MannKind

MannKind

Biotechnology
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

$1.3B

Market Cap • 11/17/2026

1991

(35 years)

Founded

2004

(22 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

3,2

P/EBITDA

87,4

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

1,3B

EV

1,5B

EV/Revenue

3,7

EV/EBITDA

102,9

EV/EBIT

-129,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,2%

Total Yield

-0,2%

Payout

0%

Retained Earnings

-3,3B

Profitability

Gross Margin

75,8%

EBITDA Margin

3,6%

EBIT Margin

—

Net Margin

—

D&A/EBITDA

119,3%

R&D/Revenue

18,7%

Capex/Revenue

2,9%

Capex/D&A

45,3%

Capex/OCF

-18,4%

SBC/OCF

—

% PPE

12%

% Goodwill

9,4%

ROE

182,9%

ROIC

—

Growth

CAGR Revenue 5Y

38,4%

CAGR Op. Income 5Y

-24%

CAGR Net Income 5Y

-1,1%

CAGR EPS 5Y

-6,4%

CAGR OCF 5Y

6,2%

Leverage

N.D./EBITDA

15,5

Debt/Equity

0%

Current Ratio

2,2

Quick Ratio

1,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium